Pharma Mar (OTCMKTS:PHMMF) Sees Significant Drop in Short Interest

Pharma Mar (OTCMKTS:PHMMF) saw a large drop in short interest in July. As of July 15th, there was short interest totaling 13 shares, a drop of 94.8% from the June 30th total of 252 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 93 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Zacks Research raised Pharma Mar to a “hold” rating in a research report on Monday, June 15th. Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. Finally, BTIG Research started coverage on shares of Pharma Mar in a research note on Thursday, April 23rd. They set a “buy” rating for the company. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Pharma Mar has a consensus rating of “Buy”.

Pharma Mar Price Performance

Shares of PHMMF stock opened at $86.09 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.44 and a current ratio of 3.02. The business has a 50 day moving average of $91.98 and a two-hundred day moving average of $93.84. Pharma Mar has a 52 week low of $77.41 and a 52 week high of $110.40.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.